Nuvalent Inc (NUVL)
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies. The company’s pipeline includes zidesamtinib (NVL-520), a ROS1-selective inhibitor being evaluated in the Phase 2 portion of the ARROS-1 Phase 1/2 trial for patients with ROS1-positive non-small cell lung cancer; neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor in the Phase 2 portion of the ALKOVE-1 trial; and NVL-330, a brain-penetrant HER2-selective inhibitor in Phase 1a/1b testing. These programs are designed to address treatment resistance, central nervous system-related adverse events, and brain metastases. Nuvalent was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Price-to-Book Ratio | Market Cap | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-NUVL
|
Not available
|
Not available
|
Not available
|
8.4x
|
9.834 B
|
0.0%
|
62.2%
|
36.5
|
69.5%
|
